Techtronic Industries remains a "Buy" despite an FY25 miss. TTNDY is guiding for a mid-to-high single-digit revenue growth in ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share ...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earn ...

Breakthrough solutions aren’t enough. New ideas can’t flourish without “bridgers”—leaders who excel at collaborating across boundaries. by Linda A. Hill, Emily Tedards and Jason Wild Innovation ...

As AI begins to transform education, work, and social life, we need to focus on developing and expanding capacities essential for human flourishing.